Wilmington-based biopharmaceutical firm, Incyte Corporation, is making waves in the hematology/oncology, and inflammation and autoimmunity space. The company has a range of clinically-proven products, including JAKAFI, used to treat adults with intermediate or high-risk myelofibrosis; MONJUVI/MINJUVI, designed for adult patients with relapsed or refractory diffuse large B-cell lymphoma; and PEMAZYRE, an oncogenic inhibitor treating various liquid and solid tumor types. Incyte is currently developing a range of promising products. Among them, axatilimab, an anti-CSF-1R monoclonal antibody developed for the treatment of patients with chronic GVHD; and parsaclisib, a PI3Kd inhibitor in Phase II clinical trials for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. The company's latest drug, retifanlimab, is currently in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer. Incyte has collaborations with several other firms, including Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited. The firm's in-license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax have helped it to expand its product portfolio.
Incyte's ticker is INCY
The company's shares trade on the NASDAQ stock exchange
They are based in Wilmington, Delaware
There are 501-1000 employees working at Incyte
It is incyte.com
Incyte is in the Healthcare sector
Incyte is in the Biotechnology industry
The following five companies are Incyte's industry peers: